

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Veröffentlichungsnummer:

11 Publication number:

11 Numéro de publication:

0 536 297

Internationale Anmeldung veröffentlicht durch die
Weltorganisation für geistiges Eigentum unter der Nummer:

WO 92/00132 (art.158 des EPf).

International application published by the World
Intellectual Property Organisation under number:

WO 92/00132 (art.158 of the EPC).

Demande internationale publiée par l'Organisation
Mondiale de la Propriété sous le numéro:

WO 92/00132 (art.158 de la CBE).

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : B01D 25/00	A1	(11) International Publication Number: WO 92/00132
		(43) International Publication Date: 9 January 1992 (09.01.92)

(21) International Application Number: PCT/US91/04457

(22) International Filing Date: 20 June 1991 (20.06.91)

(30) Priority data:
546,011 29 June 1990 (29.06.90) US

(71) Applicant: COULTER CORPORATION [US/US]; 600 West 20th Street, Hialeah, FL 33010 (US).

(72) Inventors: GLENN, Stephan, D. ; 15701 Huntridge Road, Davie, FL 33331 (US). BUTCHKO, Gregory ; 7485 Fairway Drive, Miami Lakes, FL 33014 (US). O'CONNELL, Edward ; 5500 S.W. 77th Court, Apt. 315, Miami, FL 33155 (US). SMARIGA, Paulette ; 2165 N.E. 123rd Street, North Miami, FL 33181 (US).

(74) Agents: CASS, Myron, C. et al.; Silverman, Cass & Singer, Ltd., 105 West Adams Street, 27th Floor, Chicago, IL 60603 (US).


(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published
With international search report.

(54) Title: PROCESS AND APPARATUS FOR REMOVAL OF DNA AND VIRUSES

(57) Abstract

A single filtration device (12) containing coated filter membranes (32, 38, 62, 68) and absolute pore filters (34, 36, 64, 66) is provided in which the membranes (32, 38, 62, 68) and absolute pore filters (34, 36, 64, 66) are present in two sections (30, 60) of the filter device. The filter device (12) will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6×10^5 ; remove DNA from levels of 10 $\mu\text{g}/\text{sample}$ to levels below 10 picograms per 500 mg sample of monoclonal antibody; and will remove at least 97 % of some bacterial endotoxins.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

-1-

PROCESS AND APPARATUS FOR REMOVAL OF DNA AND VIRUSES

Technical Field

The present invention relates to a process for removing DNA and viruses from physiological fluids and medicant solutions administered to humans and animals, and an apparatus for performing said process. More particularly, the invention is especially effective for removing DNA, viruses and endotoxins from biological pharmaceutical solutions and biological media, for example, DNA, viruses and endotoxins from a monoclonal antibody solution, buffer solutions or a solution of bovine serum albumin.

Background Art

One objective in the preparation of pharmaceutical solutions, buffer solutions, life support solutions, saline solutions and other such solutions which are to be administered to animals and humans is that they be as free as possible from substances which might cause an adverse reaction in the host. While a goal of zero contamination by substances such as DNA, viruses and endotoxins is always sought, in actual practice very minute amounts of such substances are sometimes present. The Food and Drug Administration (FDA) has sets standards for such substances which cannot be exceeded. Manufacturers, ever mindful that a batch of medicant may be rejected if the level of such substances is too high, continually seek new methods to ensure that their products do not exceed FDA standards. Consequently, in all phases of the manufacturing process, manufacturers seek to ensure the purity of the reagents used in the manufacture as well as the final product. Many of the medicants and other products mentioned above are either sold as aqueous solutions or are manufactured in aqueous medium. Consequently, the manufacturers seek to ensure that the water they use is free of DNA, viruses and endotoxins.

One technology that such manufacturers often use is ultrafiltration. United States Patent Nos. 4,431,545 to

-2-

Pall et al, 4,816,162 to Roskopf et al, and 4,420,398 to Castino, describe dual-module filtration to remove pathological and/or toxic substances from various fluids including water, blood and plasma. Patent No. 4,431,545
5 utilizes dual filters, one of which has a negative zeta potential and one of which has a positive zeta potential, to filter out positively and negatively charged particles. Neutral particles are removed in accordance with the pore size ratings of the filters which are 0.01 microns or larger as disclosed. Patent No. 4,816,162 describes an apparatus that removes immunoglobins, albumin and lipoproteins from blood, blood plasma or serum, but does not describe the removal of DNA or viruses. The filter in this patent is designed for use in circulating and
10 purifying blood during surgery. Patent No. 4,420,398 describes a filtration method for separating cell produced antiviral substances, including monoclonal antibodies, from the reaction "broth" in which they are produced. This patent does not indicate whether the resulting
15 species are free of viruses, endotoxins and DNA which may cause a reaction within a patient.

It is known in the prior art that multiple filtration with a 0.04 micron absolute pore size filter will remove viruses of 0.075 micron size, but not smaller
25 viruses. For example, filtration of calf serum containing MS 2 phage (0.024 micron) through 0.04 micron will not remove the virus. In those circumstances where virus can be removed, removal rate is typically 99.9 to 99.99% per filter pass. For example, using a 0.04 micron filter, applicants removed all detectable Reovirus (0.075
30 micron) from a sample containing 10^8 virus particles per milliliter sample. An article published in the April, 1990 issue of Genetic Engineering News (page 6) commented on the Food and Drug Administration's (FDA) increasing
35 emphasis on viral removal protocols with regard to the preparation of biological pharmaceuticals and the efforts being made by filter manufacturers to achieve higher degrees of virus removal.

-3-

Another contaminant which can be present in biological pharmaceuticals such as monoclonal antibodies is DNA. It is generally felt in the industry that the FDA seeks to achieve a DNA level in monoclonal antibody preparations of less than 10 picograms of DNA per dose of monoclonal antibody.

Manufacturers of biological pharmaceuticals such as monoclonal antibodies are required to establish Quality Assurance (QA) procedures to which verify that their products meet standards. In the procedures used to show compliance with the standards, it is necessary that the DNA in a sample be concentrated or solid phased (collected in solid form) from a solution of the biological pharmaceutical. It is known that DNA can be concentrated, solid phased or removed from solution by the use of diethylaminoethyl cellulose (DEAE) filter membranes. A manufacturer's literature (Schleicher & Schuell) indicates that DEAE filters will solid phase more than 90% of E. coli DNA from a solution containing 0.2 μg DNA/ml. In a more dilute solution containing 0.001 μg DNA (1 nanogram) more than 80% will be solid phased. The DEAE filters work by binding a protein such as DNA to the filter. However, a major limitation arises in the use of DEAE filters with some monoclonal antibody solutions. For example, it has been found that DNA measurements of monoclonal antibody containing buffer solution having components such as maltose can result in cause false high or low DNA values. In order to assure that the DNA assay values are accurate, these false readings must be eliminated.

Lastly, in addition to viruses and DNA, endotoxins are important contaminating substances in biological pharmaceuticals. While some manufacturers offer column packing materials which are useful in removing endotoxins from protein solutions such as solutions of monoclonal antibodies, such packing materials often result in low product yields after passage of the protein solution through the column. The DEAE filter membranes described

-4-

above have also been reported to remove endotoxins. However, we have not found the membranes to be effective in removing endotoxins from all sources. In some instances removal is high, whereas in others it is low. This variation is believed to be due to structural variation of the endotoxins themselves in the various samples. The variations in the endotoxins are, in turn, believed dependent on the source of the endotoxin itself and on the chemical treatment it has been subjected to. Having done a careful study of the extant art, we have developed a single filtration device capable of removing virus, DNA and at least some endotoxins to lower levels than previously achieved.

Disclosure of the Invention

A single filtration device containing DEAE coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The first section of the device is the DNA filter section comprising a first 0.2 micron filter, a first DEAE filter, a second DEAE filter and a second 0.2 micron filter. The second section is the virus filter section comprising a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter. The filter sections can be housed in a single filter device or, alternatively, the sections can be housed in separate housings provided that in use the housing containing the DNA filter section precedes the housing containing the virus filter section and that the two are connected. In order to achieve higher levels of filtration than that afforded by a single device, multiple devices can be combined in series. The device may be used on a large scale at the point of manufacturing or packaging a pharmaceutical solution, or it can be used on a small scale at the point of administration to a patient. In either case, the DNA and viruses are removed by passing the pharmaceutical solution through the DNA and virus filters by the use of either pressure to push the solution

-5-

through the filter elements, as when administering to a patient, or vacuum to pull the solution through the filter elements as in some manufacturing procedures.

5 The apparatus embodying the invention will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6×10^5 or approximately 99.995%, or 3×10^{10} bacteriophage (99.99999997%); remove DNA from levels of 10 μ g/sample to levels below 10 picograms per 500 mg sample of monoclonal antibody and
10 preferably below 1 picogram per sample (100 ml of water or solution); and will remove at least 97% of some bacterial endotoxins. Further, these filters units absorb less than 10% of the pharmaceutical or biological pharmaceutical, and most often 6% or less of such pharmaceuticals, particularly monoclonal antibodies and
15 bovine serum albumin.

In an alternative embodiment of the invention, the DEAE filter membranes are replaced by absolute pore filters which have been coated with DEAE, QAE (quaternary aminoethyl salts), QAM (quaternary aminomethyl salts) or
20 other like quaternary salts. For example, the first and second DEAE filters can be replaced by 0.04 micron filters coated with QAE or QAM.

In an alternative embodiment of the invention, an improved apparatus wherein DEAE functional groups, QAE, QAM or other quaternary amine functional groups are bonded directly directly to one or more of the 0.2, 0.1 and 0.04 micron absolute pore size filters, said functionalized absolute pore filters thereby replacing
25 the DEAE cellulose filters.

Brief Description of the Drawings

Fig. 1 is a perspective view of single unit of filter apparatus embodying the invention;

Fig. 2 is an exploded view of the apparatus shown in
35 Fig. 1;

Fig. 3 is a perspective view of a multiple unit filter apparatus embodying the invention;

Fig. 4 is an exploded view of the apparatus shown in Fig. 3.

-6-

Best Mode for Carrying out the Invention

Referring to Fig. 1, the invention is a filter device 12 comprising a two-piece filter housing part having a top part 14 with inlet port 18, a base part 16 with outlet port 20 and a series of internal elements (not shown) with said top part and base part being joined together in a leakproof manner; for example, by screwing the two parts together, by ball and socket attachment or other such means.

Figure 2 is an exploded view of apparatus of the invention. The apparatus comprises the visible external members 14, 16, 18 and 20 as described above and internal elements, said internal elements being a first flat filter support 24 having a plurality of channels 26 extending through the thickness of the support; a first sealing member 28 extending a lateral distance inward from the inner wall of the filter housing; a first filter section 30 having filter elements 32, 34, 36 and 38 in sequential facial contact from one to the other throughout; a filter support 40 with a flat top face 42 in contact with the bottom face of filter element 38, a plurality of channels 26 extending through the thickness of the support and a plurality of rigid legs 44 at the outer edge of the bottom face of said support; a second flat filter support 46 having a plurality of channels 26 extending through the thickness of the support and whose top face 48 is in contact with legs 44; a second sealing member 50; a second filter section 60 having filter elements 62, 64, 66 and 68 in sequential facial contact from one to the other throughout; a third flat filter support 70 having a plurality of channels 26 extending through the thickness of said support; and wherein the top to bottom face contact of the element is 28 to 24, 32 to 28, 34 to 32, 36 to 34, 38 to 36, 40 to 38, 50 to 46, 62 to 50, 64 to 62, 66 to 64, 80 to 66 and 70 to 68; and the top of face of element 24 is supported by the interior of top housing 14 and the bottom fact of element 72 is supported by the interior of housing 16; and wherein sealing said interior

-7-

elements by joining said top and base housing causes a pressure to be exerted on said sealing members 28 and 50 causing said sealing members to seal to the walls of said housing thereby preventing flow around filter sections 30 and 60, and forcing said flow to occur only through said filter sections.

Referring to Fig. 3, a second embodiment of the invention is a two section filter device 12 having a first DNA removal filter unit 4 and a second virus removal unit 6 joined by a connecting means 80.

Fig. 4 is an exploded view of the two unit filter device as shown in FIG. 3 comprising a first DNA removal filter unit having a top filter housing part 14 with inlet port 18 and a base filter housing part 16 with outlet port 20, and internal members flush to the interior walls and sequentially in facial contact with each other; said internal members being a first flat filter support 24 having a plurality of channels 26 extending through the thickness of the support; a sealing member 28 in contact with the inner side walls of said housing and extending a lateral distance inward from the inner wall; a DNA filter section 30 having filter elements 32, 34, 36 and 38; a second flat filter support 72 having a plurality of channels extending through the thickness of the support; and a second virus removal filter unit 6 having a top filter housing part 15 with inlet port 19 and a base filter housing part 17 with outlet port 21 and internal members which are sequentially in facial contact with each other; said internal members being a first flat filter support 46 having a plurality of channels extending through the thickness of said support; a first sealing member 50 in contact with the inner side walls of said housing and extending a lateral distance inward from said inner wall; a virus filter section 60 having filter elements 62, 64, 66 and 68; and a filter support member 62 having a plurality of channels 26 extending through the thickness of said support; and a connecting member 80 joining said DNA filter unit 4 and said virus removal

-8-

filter unit 6 by connecting outlet port 20 and inlet port 19; wherein the top to bottom face contact of the elements is 28 to 24, 32 to 28, 34 to 32, 36 to 34, 38 to 36, 72 to 38, 50 to 46, 62 to 50, 64 to 62, 66 to 64, 68 to 66, and 70 to 68; and top face of elements 24 and 46 is supported by the interior of their respective housings 14 and 15 and the bottom face of elements 70 and 72 is supported by the interior of their respective housings 16 and 17; and whereby enclosing said interior elements by joining respective top and base housings parts causes a pressure to be exerted on said sealing members thereby preventing flow around filter section 30 and 60, and forcing said flow to occur only through said respective filter sections; and said first DNA removal filter part and said second virus removal filter part being joined by connecting means 80 attached to parts 19 and 20.

The filter units of as described above can be in any size and shape -round, square, rectangular- possible, subject only to limitation of the availability of size and shape of the filter material for filter sections 30 and 60. The filter units can be sized to handle commercially useful quantities of water for use in the manufacture or preparation of buffer solution, pharmaceuticals, and pharmaceuticals solutions and the like. The filter can be used at any point in a manufacturing processes where a new aqueous material is added and is especially useful in removing DNA, viruses and endotoxins in the packaging step at the end of the manufacturing process. In addition, the filter system of the present invention can be used in conjunction with a device for administering a physiological or a pharmaceutical solution to a patient; for example, the filter system can be built into or placed into a hypodermic syringe. In all instances of use, the solution being filtered passes through the DNA removal filter section and then passes through the virus removal filter section

The filter elements of the filter apparatus described above are a combination of diethylaminoethyl cel-

-9-

lulose and absolute pore filters. These filters, when used in the apparatus of this invention, will remove on 0.1 micron type-C retrovirus with an efficiency of 4.6×10^5 or higher, remove DNA to level of 10 micrograms/ml to levels below 1 picogram/ml and will remove about 97% of some bacterial endotoxins. In addition, the filter elements of the present invention absorb 6% or less of proteins from the solution under treatment: for example, monoclonal antibody or bovine serum albumin solution. In the preferred embodiment of the invention elements 32 and 38 are 0.2 micron absolute pore filters; elements 34 and 36 are DEAE coated filters such as, for example, Schleicher & Schuell's NA45 filters; elements 62 and 64 are 0.1 micron absolute filters; and elements 66 and 68 are 0.04 micron absolute pore filters.

In the preferred embodiment of the invention, infectious virus particles of about 0.108 micron size can be removed with an efficiency of at least 99.99% per passage through the filtration apparatus. Higher efficiencies can be obtained by using two or more of the filter apparatus in series.

The preferred filter apparatus of the invention provides for a synergistic effect upon use of the filter elements as specified. The smallest absolute pore filter of the invention is 0.04 microns. Manufacturer's literature for the DEAE filters state that the pore size is 0.45 microns. However, as stated above and shown in the examples below, virus as small as 0.018 micron (the minimum virus particle size) can be removed. While the exact nature of the synergistic effect is not known, complete removal of virus 55% smaller than the smallest pore size filter element was not anticipated.

In a process utilizing the device of this invention, the water, aqueous buffer solutions and pharmaceutical solutions, including biological pharmaceutical solutions, have a pH in the range of 3 to 9. Further, these solutions have a specific salt content of less than 0.5 Molar, said specific salts being one or more selected

-10-

from the group consisting of the lithium, sodium, potassium or ammonium salts of the phosphate, chloride, bromide, iodide, sulfate and acetate anions. When utilizing the device of this invention, solutions are first passed through the DNA removal section prior to passage through the virus removal section.

The following examples are given to illustrate the utility of the present invention and are not to be construed as limiting the scope of the invention.

Example 1. Virus Removal

The internal elements of the filter unit of the invention were assembled using eight filter element in the sequence 0.2 micron, DEAE, DEAE, 0.2 micron, 0.1 micron, 0.1 micron, 0.04 micron and 0.04 micron. The 0.2, 0.1 and 0.04 micron elements were absolute pore filters, and the DEAE elements were NA 45 filters (Schleicher & Schuell). The units were sealed in autoclavable syringes and were autoclaved or gas sterilized using standard procedures. The sterilized syringes containing the filter elements were sent to Microbiological Associates, Inc., Life Sciences Center, 9900 Blackwell Road, Rockville, Maryland 20850 for evaluation with monoclonal antibody solutions spiked with mouse xenotropic retrovirus of similar size to type C retrovirus (0.1 micron v 0.104 micron respectively). Each syringe filter device was evaluated against one sample of retrovirus spiked monoclonal antibody. By $S+L^-$ assay, the samples contained 4.37×10^5 , 5.6×10^5 and 4.1×10^5 FFU/ml.

[FFU/ml = (mean number of foci/dish x $\frac{1}{\text{volume/dish}} \times \frac{1}{\text{dilution}}$)]

After passage of the test samples through the syringe filter units, the filtrates were re-analyzed in triplicate for retrovirus. No retrovirus found in any of the three monoclonal antibody filtrates. Antibody recovery

-11-

was greater than 90%.

Example 2. Removal Of Bacteriophage By DNA/ Virus
Removal Filters.

The maximum concentration of xenotropic retrovirus
5 attainable is about 10^6 FFU/ml. In order to validate the
DNA/Virus removal filters of this invention for higher
virus particle removal efficiencies, bacteriophage T4
(approximately 0.1 micron) was chosen as a second model
virus. The assay for bacteriophage T4 concentration was
10 the formation of plaques (PFU) on a lawn of Escherichia
coli B (ATCC 11303). The bacteriophage T4 was grown to
maximum concentration (9.9×10^{10} PFU/ml) and the un-
diluted bacteriophage solution was divided into three
aliquots. Each aliquot was filtered through a separate
15 DNA/Virus removal filter device. The concentration of
bacteriophage T4 in the filtrate was assayed by dilution
and plating on dishes of E. coli. None of the three fil-
trates contained viable virus. The assay has an uncer-
tainty of 3.3 FFU. These results indicate that the
20 DNA/Virus removal filter device of the present invention
is capable of reducing the concentration of an 0.1 micron
bacteriophage by at least 3.0×10^{10} fold (99.99999997%).
Similar results should be obtainable with viruses of
similar size, approximately 0.1 micron, such as type C
25 retrovirus. Type C retrovirus has been found to be a
contaminant in the conditioned raw material for mono-
clonal antibody pharmaceutical. To the inventors' know-
ledge, no single pass through any filter as previously
achieved this level of virus removal. Using the filter
30 device of the present invention should reduce the con-
centration of type C retrovirus in the conditioned raw
material by at least 3×10^{10} fold. Thus, solutions con-
taining nominal virus counts on the order of 10^7 should
be able to be filtered to an undetectable virus level
35 with a 1000 fold safety margin. In those cases where the
virus load of a solution is higher, over 10^7 , the
solution can be filtered two or more times to obtain a

-12-

solution having an undetectable virus level. Using two of the filter devices of the present invention in series would allow the removal of approximately 10^{17} - 10^{18} virus particles per ml $[(3 \times 10^{10}) \times (3 \times 10^{10}) / 1000 = 9 \times 10^{17}]$.

Example 3. DNA Removal From Spiked Antibody Solutions

Monoclonal antibody solutions containing 400 mg of antibody each and DNA were filtered through the DNA/virus removal filter unit of the invention. DNA analysis before and after filtration showed 727 pg and 442 pg of DNA per sample before filtration; and 5pg and 1 pg DNA, respectively, after filtration (99.3% and 99.8% removal).

Example 4. DNA Removal From Commercial Antibody Solutions

Analysis of commercial monoclonal antibody solutions indicated that there is significant DNA contamination. The analysis was performed using an assay kit from FMC Bio Products, Rockland, Maine (FMC assay) for the detection of DNA solid-phased on Nylon 66 membranes. Five lots of DNA containing monoclonal antibody solution were analyzed for DNA before and after filtration through a filter device of the invention: All filtered solutions had less than 10 picograms of DNA per dose of antibody and two of the five showed less than 1 picogram per dose. The results are shown in Table 1.

Table 1 SUMMARY of DNA REMOVAL from antibody products

Product No.	Mean DNA		Concentration
	Before Filtration		After Filtration
	pg DNA/mg Mab: pg DNA/dose		pg DNA/dose
1	0.65	260	2.6
2	0.30	120	0.4
3	0.34	3.4	2.6
4	0.13	1.3	3.1
5	0.14	140	0

-13-

Example 5.

DNA Removal Validation

In order to validate DNA removal for commercial purposes, the DNA/Virus removal filters were challenged with 500 mg samples of a pharmaceutical grade monoclonal antibody (B1) in buffer spiked with 100 micrograms of hybridoma produced DNA. The DNA used in the validation was purified from the same cell culture medium used to produce monoclonal antibodies and was as similar as possible to the DNA actually encountered in the production of the antibody. Three antibody solutions were spiked with the DNA. Two unspiked antibody solutions, two buffer (only) solutions without DNA and two buffer (only) solutions spiked with 100 micrograms of DNA were used as controls. The actual level of DNA in the spiked solutions was determined by means of a fluorescent DNA assay technique. The spiked antibody solutions were found to have actual DNA levels of 81, 92 and 74 micrograms per sample. The spiked buffer solutions were found to have actual DNA levels of 89 and 96 micrograms per sample. All solutions samples were equal volume.

Each of the test solutions (9 solutions total) was filter through a separate 25mm DNA/Virus removal filter device. The residual DNA in each filtrate was concentrated, solid phased and quantified in duplicate using standard FMC DNA assay techniques. The quantity of DNA in each assay was determined from a standard curve of purified hybridoma DNA run in the same assay. For the standard curve, the color intensities of the sample bands, measured by the instrument's reflection densitometer, are measured as peak heights in centimeters. The standard curve data is linearly transformed by a log-logit transformation where the peak heights are converted to a logit (relative to a standard that will give maximum color development and a blank) versus the log of the picograms of DNA standard added. Test samples were then interpolated from the standard curve of DNA to color intensity. The results are given in Table 2 and indicate

that a single pass through the DNA/Virus removal filter is capable of reducing the DNA levels by about 10^7 fold to approximately 10 picograms DNA per 500 mg of monoclonal antibody (mean = 12.3 pg DNA/500mg antibody). The mean value for an equal volume of unspiked buffer (only) is 6.2 pg. Therefore, the mean net DNA detected in the filtered, spiked antibody solution is 6.1 pg DNA/500 mg antibody.

Table 2

10	Sample	DNA Spike	DNA Detected in sample after DNA spiking	% Recovery of protein concentration (Lowry)	Mean total DNA detected Mean after filtration
15	B1 500 mg	100 ug	81 ug	98.9%	16.5 pg
	B1 500 mg	100 ug	92 ug	98.0%	8.6 pg 12.3pg
	B1 500 mg	100 ug	74 ug	96.7%	11.7 pg
	B1 500 mg	0	0	96.3%	3.3 pg
	B1 500 mg	0	0	92.8%	3.2 pg 3.2pg
20	Buffer	100 ug	89 ug	N/A	16.9 pg
	Buffer	100 ug	96 ug	N/A	3.3 pg 10.1pg
	Buffer	0	0	N/A	9.8 pg
	Buffer	0	0	N/A	2.6 pg 6.2pg

* total DNA in 500 mg sample of monoclonal antibody (mean observation of samples assayed in duplicate)

Example 6 Endotoxin Removal

A 100ml solution of 50mg/ml bovine serum albumin in 10% maltose-phosphate buffer solution contaminated with DNA and an endotoxin was filtered through a 47 mm DNA/virus removal filtration device. The starting

SUBSTITUTE SHEET

-15-

solution contained 248 pg/ml DNA and 1966 endotoxin units ml (EU/ml).

5 First, middle and end 20ml portions of the filtrate were collected and analyzed. No DNA was detected in any analyzed portion of filtrate. Endotoxin levels were: first= 30.72 EU/ml, middle= 30.72 EU/ml and last= 61.44 EU/ml. Endotoxin removal in the end sample was 96.9%. Solution recovery was 95% (95ml) with no change in protein concentration.

Claims

1. A process for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions comprising, passing one of said aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions through a first DNA filter section and a second virus filter section, wherein said DNA, viruses and endotoxins are substantially removed; and collecting said aqueous buffer solutions, aqueous pharmaceutical solutions or aqueous biological pharmaceutical solutions; said first DNA filter section having:

- (i) a first absolute pore filter,
 - (ii) a first and second filter selected from one of (a) a DEAE cellulose filter membrane and (b) an absolute pore filter coated with at least one of DEAE cellulose, quaternary aminoethyl salts and quaternary aminomethyl salts, and
 - (iii) a second absolute pore filter;
- and said second virus filter section having absolute pore filters of smaller pore diameter than the absolute pore filters in the DNA filter section.

2. A process in accordance with claim 1 wherein the yield of pharmaceuticals or biological pharmaceuticals, in the filtered solutions is 90% or higher compared to the starting solution.

3. A process in accordance with claim 1 wherein the virus removal is 99.9999997% or higher when the virus is 0.100 microns or larger, and the yield of pharmaceutical or biological pharmaceutical in the filtered solution of same of 90% or higher compared to the starting solution.

4. A process in accordance with claim 1 wherein said DNA in the filtered solutions is less than 10 picograms per 100 ml of solution.

5. A process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions

-17-

have a pH in the range of 3 to 9.

6. A process in accordance with claim 1 wherein the aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions each have a specific salt content of less than 0.5 Molar, said specific salt being at least one selected from the group consisting of the lithium, sodium, potassium and ammonium salts of the phosphate, chloride, bromide, iodide, sulfate and acetate anions.

7. A process in accordance with claim 1 wherein said DNA in the filtered solutions is less than 1 picogram per 100 ml of solution.

8. A process for the removal of DNA and viruses from aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, comprising passing either one of the solutions through a first DNA filter section and a second virus filter section to obtain a filtered aqueous pharmaceutical solution or a filtered aqueous biological pharmaceutical solution having substantially reduced DNA and virus levels, said solutions passing through:

(a) a first DNA filter section comprising a first 0.2 micron absolute pore filter, a first diethylaminoethyl cellulose filter, a second diethylaminoethyl cellulose filter and a second 0.2 micron absolute pore filter, and

(b) a second virus filter section comprising a first 0.1 micron absolute pore filter, a second 0.1 micron absolute pore filter, a first 0.04 micron absolute pore filter and a second 0.04 micron absolute pore filter; and collecting the filtered solutions.

9. A process in accordance with claim 8 wherein the yield of the pharmaceutical or biological pharmaceutical in the filtered solution is 90% or higher.

10. A process in accordance with claim 8 wherein the virus removal is 99.99999997% or higher when the virus is 0.100 microns or larger, and the yield of the pharmaceutical or biological pharmaceutical in the fil-

-18-

tered solution is 90% or higher.

11. A process in accordance with claim 8 wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is reduced to less than 10 picograms per 100 ml of solution.

12. A process in accordance with claim 8 wherein the pharmaceutical solution or biological pharmaceutical solution has a pH in the range of 6 to 8.

13. A process in accordance with claim 8 wherein the pharmaceutical or biological pharmaceutical has a specific salt content, excluding salts of pharmaceuticals or biological pharmaceuticals, of less than 0.5 Molar, said specific salts being at least one selected from the group consisting the lithium, sodium, potassium and ammonium salts of the phosphate, chloride, bromide, iodide, sulfate and acetate anions.

14. A process in accordance with claim 1 or 8 wherein said aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions are passed through said DNA filter section and said virus filter section by a vacuum means or a pressure means.

15. A process in accordance with claim 8, wherein the DNA in the filtered pharmaceutical or biological pharmaceutical solution is reduced to less than 1 picogram per 100 ml of solution.

16. An improved apparatus for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said apparatus having a housing with suitable inlet/outlet means, internal gaskets and filter supports, and internal filters wherein the improvement comprises a first DNA filter section having, from inflow to outflow, a first 0.2 micron filter, a first diethylaminoethyl cellulose filter, a second diethylaminoethyl cellulose filter and a second 0.2 micron filter, the filters having face-to-face contact; and a second virus filter section having, from inflow to

-19-

outflow, a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter, said filters having face-to-face contact.

17. An improved apparatus in accordance with claim
5 16 wherein said 0.2, 0.1 and 0.04 filters are absolute pore filters.

18. The improved apparatus in accordance with claim 16 wherein said apparatus is capable of removing DNA to a level of less than 10 picograms per 100 ml of solution.

10 19. The improved apparatus of claim 16 wherein said apparatus is capable of removing 99.9999997% of virus when the virus is 0.100 microns or larger.

20. The improved apparatus of claim 16 wherein the apparatus gives a yield of pharmaceutical or biological
15 pharmaceutical in the filtered solution of 90% or higher compared to the unfiltered solution.

21. The improved apparatus of claim 16 where the solution to be filtered is passed through said apparatus by pressure or vacuum means.

20 22. The improved apparatus of claim 16 wherein said apparatus is a means of administration of said aqueous buffer solution, aqueous pharmaceutical solution or aqueous biological pharmaceutical solution to a patient which means contains said DNA and virus filter sections.

25 23. The improved apparatus of claim 16 wherein said apparatus is a syringe filtration device containing said DNA and Virus removal filters.

24. An improved apparatus for the removal of DNA, endotoxins and viruses from aqueous buffer solutions,
30 aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said apparatus having a housing with suitable inlet/outlet means, internal gaskets and filter supports, and internal filters wherein the improvement comprises a first DNA filter section having,
35 from inflow to outflow, a first 0.2 micron filter, first and second absolute pore filters coated with at least one selected from the group consisting of DEAE cellulose, QAE, QAM and other quaternary ammonium salts, a second

0.2 micron filter, the filters having face-to-face contact; and a second virus filter section having, from inflow to outflow, a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter, said filters having face-to-face contact.

25. The improved apparatus in accordance with claim 14, wherein said apparatus is capable of removing DNA to a level of less than 1 picogram per ml of solution.

26. An improved apparatus for the removal of DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions, said apparatus having a housing with suitable inlet/outlet means, internal gaskets and filter supports, and internal filters wherein the improvement comprises a first DNA filter section having, from inflow to outflow, a first 0.2 micron filter, a second 0.2 micron filter, the filters having face-to-face contact; and a second virus filter section having, from inflow to outflow, a first 0.1 micron filter, a second 0.1 micron filter, a first 0.04 micron filter and a second 0.04 micron filter, said filters having face-to-face contact; wherein at least one of the absolute pore filters is coated with at least one of the group consisting of DEAE, QAE, QAM and other quaternary ammonium salts.

27. Apparatus for removing DNA, endotoxins and viruses from aqueous buffer solutions, aqueous pharmaceutical solutions and aqueous biological pharmaceutical solutions comprising, a housing having inlet and outlet means for such solutions, a stacked assembly of filter sections and internal gasketing and support means for said filter sections, said assembly including a DNA filter section and a virus filter section constructed and arranged to substantially remove DNA, virus and endotoxins from such solution passed therethrough, and means for collecting said solutions after such removal of dna, endotoxins and viruses.

28. Apparatus according to claim 27 in which said

-21-

DNA filter section has

(i) a first absolute pore filter,

(ii) a first and second filter selected from one of
(a) a DEAE cellulose filter membrane and (b) an absolute
5 pore filter coated with at least one of DEAE cellulose,
quaternary aminoethyl salts and quaternary aminomethyl
salts, and

(iii) a second absolute pore filter;

10 and said virus filter section has absolute pore filters
of smaller pore diameter than the absolute pore filters
in the DNA filter section.

Fig. 1




Fig. 2






Fig. 4



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04457

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): BOLD 25/00 US Cl.: 210/641																													
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">U.S.</td> <td style="border: none;">210/641, 652, 653, 655, 321.64, 321.84, 335, 446, 500.29, 506 507m508; 422/1, 101; 435/311; 935/19</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 5px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System	Classification Symbols	U.S.	210/641, 652, 653, 655, 321.64, 321.84, 335, 446, 500.29, 506 507m508; 422/1, 101; 435/311; 935/19																							
Classification System	Classification Symbols																												
U.S.	210/641, 652, 653, 655, 321.64, 321.84, 335, 446, 500.29, 506 507m508; 422/1, 101; 435/311; 935/19																												
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; font-size: x-small;">Category ¹⁰</th> <th style="width: 70%; font-size: x-small;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; font-size: x-small;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>US, A, 4,431,545 (PALL) 14 February 1984 See entire document.</td> <td style="text-align: center; vertical-align: top;">27</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>JP, A, 57-197085 (DIACEL CHEM IND) 03 December 1982</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 4,869,826 (WANG) 26 September 1989</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 4,420,398 (ASTINO) 13 December 1983</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 4,168,300 (ANDERSSON) 18 September 1979</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 4,935,142 (STERNBERG) 19 June 1990</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 4,473,474 (OSTREICHER) 25 September 1984</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US, A, 3,676,335 (LACEY) 11 July 1972</td> <td style="text-align: center; vertical-align: top;">1-28</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	US, A, 4,431,545 (PALL) 14 February 1984 See entire document.	27	A	JP, A, 57-197085 (DIACEL CHEM IND) 03 December 1982	1-28	A	US, A, 4,869,826 (WANG) 26 September 1989	1-28	A	US, A, 4,420,398 (ASTINO) 13 December 1983	1-28	A	US, A, 4,168,300 (ANDERSSON) 18 September 1979	1-28	A	US, A, 4,935,142 (STERNBERG) 19 June 1990	1-28	A	US, A, 4,473,474 (OSTREICHER) 25 September 1984	1-28	A	US, A, 3,676,335 (LACEY) 11 July 1972	1-28
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																											
X	US, A, 4,431,545 (PALL) 14 February 1984 See entire document.	27																											
A	JP, A, 57-197085 (DIACEL CHEM IND) 03 December 1982	1-28																											
A	US, A, 4,869,826 (WANG) 26 September 1989	1-28																											
A	US, A, 4,420,398 (ASTINO) 13 December 1983	1-28																											
A	US, A, 4,168,300 (ANDERSSON) 18 September 1979	1-28																											
A	US, A, 4,935,142 (STERNBERG) 19 June 1990	1-28																											
A	US, A, 4,473,474 (OSTREICHER) 25 September 1984	1-28																											
A	US, A, 3,676,335 (LACEY) 11 July 1972	1-28																											
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>																													
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> Date of the Actual Completion of the International Search 03 September 1991 International Searching Authority ISA/US </td> <td style="width: 50%; border: none; vertical-align: top;"> Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold;">24 SEP 1991</div> Signature of Authorized Officer W. Gary Jones </td> </tr> </table>			Date of the Actual Completion of the International Search 03 September 1991 International Searching Authority ISA/US	Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold;">24 SEP 1991</div> Signature of Authorized Officer W. Gary Jones																									
Date of the Actual Completion of the International Search 03 September 1991 International Searching Authority ISA/US	Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold;">24 SEP 1991</div> Signature of Authorized Officer W. Gary Jones																												

Fig. 1




Fig. 2




Fig. 4

Fig. 3

